Bio Orchestra Co., Ltd. announced that it has received KRW 54,000 million in a round of funding on February 22, 2022. The transaction included participation from DAYLI Partners Co., Ltd., IMM Investment Corp., SBI Investment KOREA Co., Ltd., returning investor LSK Investment, E& Venture Partners, Smilegate Investment, Inc., Quantum Ventures Korea, Widwin Investment Co., Ltd., GS Holdings Corp., returning investor Chong Kun Dang Holdings Corp. and Chong Kun Dang Pharmaceutical Corp and NH Securities.